Literature DB >> 33414541

Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast.

Sunil S Badve1, Sanghee Cho2, Yesim Gökmen-Polar3, Yunxia Sui2, Chrystal Chadwick2, Elizabeth McDonough2, Anup Sood2, Marian Taylor4, Maria Zavodszky2, Puay Hoon Tan5, Michael Gerdes2, Adrian L Harris4, Fiona Ginty2.   

Abstract

BACKGROUND: There is limited knowledge about DCIS cellular composition and relationship with breast cancer events (BCE).
METHODS: Immunofluorescence multiplexing (MxIF) was used to image and quantify 32 cellular biomarkers in FFPE DCIS tissue microarrays. Over 75,000 DCIS cells from 51 patients (median 9 years follow-up for non-BCE cases) were analysed for profiles predictive of BCE. K-means clustering was used to evaluate cellular co-expression of epithelial markers with ER and HER2.
RESULTS: Only ER, PR and HER2 significantly correlated with BCE. Cluster analysis identified 6 distinct cell groups with different levels of ER, Her2, cMET and SLC7A5. Clusters 1 and 3 were not significant. Clusters 2 and 4 (high ER/low HER2 and SLC7A5/mixed cMET) significantly correlated with low BCE risk (P = 0.001 and P = 0.034), while cluster 6 (high HER2/low ER, cMET and SLC7A5) correlated with increased risk (P = 0.018). Cluster 5 (similar to cluster 6, except high SLC7A5) trended towards significance (P = 0.072). A continuous expression score (Escore) based on these 4 clusters predicted likelihood of BCE (AUC = 0.79, log-rank test P = 5E-05; LOOCV AUC = 0.74, log-rank test P = 0.006).
CONCLUSION: Multiplexed spatial analysis of limited tissue is a novel method for biomarker analysis and predicting BCEs. Further validation of Escore is needed in a larger cohort.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33414541      PMCID: PMC7961015          DOI: 10.1038/s41416-020-01216-6

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  1 in total

1.  Loss of constitutive ABCB1 expression in breast cancer associated with worse prognosis.

Authors:  João Marcos de Azevedo Delou; Giselle Maria Vignal; Vanessa Índio-do-Brasil; Maria Theresa de Souza Accioly; Taiana Sousa Lopes da Silva; Diogo Nascimento Piranda; Marcelo Sobral-Leite; Marcelo Alex de Carvalho; Márcia Alves Marques Capella; Rosane Vianna-Jorge
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-06-10
  1 in total
  3 in total

Review 1.  Ductal Carcinoma In Situ of Breast: From Molecular Etiology to Therapeutic Management.

Authors:  Shelby Lynn Hophan; Olena Odnokoz; Huiping Liu; Yuan Luo; Seema Khan; William Gradishar; Zhuan Zhou; Sunil Badve; Mylin A Torres; Yong Wan
Journal:  Endocrinology       Date:  2022-04-01       Impact factor: 4.736

Review 2.  Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

Authors:  Anna K Casasent; Mathilde M Almekinders; Charlotta Mulder; Proteeti Bhattacharjee; Deborah Collyar; Alastair M Thompson; Jos Jonkers; Esther H Lips; Jacco van Rheenen; E Shelley Hwang; Serena Nik-Zainal; Nicholas E Navin; Jelle Wesseling
Journal:  Nat Rev Cancer       Date:  2022-10-19       Impact factor: 69.800

Review 3.  Next-Generation Pathology Using Multiplexed Immunohistochemistry: Mapping Tissue Architecture at Single-Cell Level.

Authors:  Francesca Maria Bosisio; Yannick Van Herck; Julie Messiaen; Maddalena Maria Bolognesi; Lukas Marcelis; Matthias Van Haele; Giorgio Cattoretti; Asier Antoranz; Frederik De Smet
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.